Oruka Therapeutics Inc Financials
This page shows Oruka Therapeutics Inc (ORKA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Oruka Therapeutics Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Oruka Therapeutics Inc generates $0.84 in operating cash flow (-$88.2M OCF vs -$105.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Oruka Therapeutics Inc's EBITDA was -$122.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 38.4% from the prior year.
Oruka Therapeutics Inc reported -$105.4M in net income in fiscal year 2025. This represents a decrease of 25.9% from the prior year.
Cash & Balance Sheet
Oruka Therapeutics Inc generated -$88.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 52.4% from the prior year.
Oruka Therapeutics Inc held $46.9M in cash against $0 in long-term debt as of fiscal year 2025.
Oruka Therapeutics Inc had 49M shares outstanding in fiscal year 2025. This represents an increase of 30.1% from the prior year.
Margins & Returns
Oruka Therapeutics Inc's ROE was -22.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.4 percentage points from the prior year.
Capital Allocation
Oruka Therapeutics Inc invested $100.6M in research and development in fiscal year 2025. This represents an increase of 34.1% from the prior year.
Oruka Therapeutics Inc invested $209K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 10.6% from the prior year.
ORKA Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $29.0M+20.3% | $24.1M+20.9% | $19.9M | N/A | $25.7M+37.6% | $18.7M+11217.0% | $165K |
| SG&A Expenses | N/A | $5.1M+17.8% | $4.3M-15.9% | $5.2M | N/A | $3.8M+33.3% | $2.8M+21.7% | $2.3M |
| Operating Income | N/A | -$34.1M-20.0% | -$28.4M-13.3% | -$25.1M | N/A | -$29.4M-37.0% | -$21.5M-766.0% | -$2.5M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $504K-32.8% | $750K+250.5% | $214K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$30.3M-23.2% | -$24.6M-17.0% | -$21.0M | N/A | -$28.6M-28.7% | -$22.2M-1007.2% | -$2.0M |
| EPS (Diluted) | N/A | N/A | $-0.46-15.0% | $-0.40 | N/A | $-1.46+79.0% | $-6.96-4871.4% | $-0.14 |
ORKA Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $488.6M-4.1% | $509.3M+42.5% | $357.4M-5.2% | $377.1M-4.8% | $396.0M-4.4% | $414.1M+1123.5% | $33.8M-7.8% | $36.7M |
| Current Assets | $343.9M-3.2% | $355.2M+7.0% | $332.0M-5.7% | $352.1M-6.6% | $376.9M-8.7% | $412.9M+1121.0% | $33.8M-7.8% | $36.7M |
| Cash & Equivalents | $46.9M-48.6% | $91.3M+39.5% | $65.4M-21.7% | $83.6M+35.7% | $61.6M-85.0% | $410.9M+1134.5% | $33.3M-7.3% | $35.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $16.7M-25.7% | $22.5M+63.0% | $13.8M+11.2% | $12.4M-10.2% | $13.8M-26.9% | $18.9M-69.9% | $62.8M+43.6% | $43.8M |
| Current Liabilities | $15.4M-26.7% | $21.0M+73.1% | $12.1M+3.3% | $11.7M-10.1% | $13.0M-27.7% | $18.0M+1319.3% | $1.3M-19.6% | $1.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $471.9M-3.1% | $486.8M+41.7% | $343.6M-5.8% | $364.7M-4.6% | $382.2M+11.6% | $342.4M+1281.4% | -$29.0M-310.6% | -$7.1M |
| Retained Earnings | -$189.2M-18.5% | -$159.6M-23.4% | -$129.3M-23.5% | -$104.7M-25.1% | -$83.7M-44.5% | -$57.9M+70.0% | -$193.4M-1.4% | -$190.8M |
ORKA Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$22.6M-4.6% | -$21.6M+6.7% | -$23.1M-10.9% | -$20.9M-10.9% | -$18.8M+32.4% | -$27.8M-956.1% | -$2.6M-72.4% | -$1.5M |
| Capital Expenditures | $63K-36.4% | $99K+191.2% | $34K+161.5% | $13K-27.8% | $18K | N/A | N/A | N/A |
| Free Cash Flow | -$22.7M-4.4% | -$21.7M+6.4% | -$23.2M-11.0% | -$20.9M-10.9% | -$18.8M | N/A | N/A | N/A |
| Investing Cash Flow | -$22.0M+82.0% | -$122.4M-2619.5% | $4.9M-88.7% | $42.9M+113.0% | -$330.0M | N/A | $0 | $0 |
| Financing Cash Flow | $298K-99.8% | $169.9M | N/A | N/A | -$526K-100.1% | $423.7M+3026635.7% | $14K | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ORKA Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -6.2%+0.9pp | -7.1%-1.4pp | -5.8% | N/A | -8.4% | N/A | N/A |
| Return on Assets | N/A | -5.9%+0.9pp | -6.9%-1.3pp | -5.6% | N/A | -6.9%+58.8pp | -65.7%-60.3pp | -5.5% |
| Current Ratio | 22.37+5.4 | 16.94-10.5 | 27.42-2.6 | 30.03+1.1 | 28.89+6.0 | 22.89-3.7 | 26.61+3.4 | 23.19 |
| Debt-to-Equity | 0.04-0.0 | 0.050.0 | 0.040.0 | 0.030.0 | 0.04-0.0 | 0.06+2.2 | -2.17+4.0 | -6.20 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Oruka Therapeutics Inc profitable?
No, Oruka Therapeutics Inc (ORKA) reported a net income of -$105.4M in fiscal year 2025.
What is Oruka Therapeutics Inc's EBITDA?
Oruka Therapeutics Inc (ORKA) had EBITDA of -$122.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Oruka Therapeutics Inc's return on equity (ROE)?
Oruka Therapeutics Inc (ORKA) has a return on equity of -22.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Oruka Therapeutics Inc's free cash flow?
Oruka Therapeutics Inc (ORKA) generated -$88.4M in free cash flow during fiscal year 2025. This represents a -52.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Oruka Therapeutics Inc's operating cash flow?
Oruka Therapeutics Inc (ORKA) generated -$88.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Oruka Therapeutics Inc's total assets?
Oruka Therapeutics Inc (ORKA) had $488.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Oruka Therapeutics Inc's capital expenditures?
Oruka Therapeutics Inc (ORKA) invested $209K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Oruka Therapeutics Inc spend on research and development?
Oruka Therapeutics Inc (ORKA) invested $100.6M in research and development during fiscal year 2025.
What is Oruka Therapeutics Inc's current ratio?
Oruka Therapeutics Inc (ORKA) had a current ratio of 22.37 as of fiscal year 2025, which is generally considered healthy.
What is Oruka Therapeutics Inc's debt-to-equity ratio?
Oruka Therapeutics Inc (ORKA) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Oruka Therapeutics Inc's return on assets (ROA)?
Oruka Therapeutics Inc (ORKA) had a return on assets of -21.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Oruka Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Oruka Therapeutics Inc (ORKA) had $46.9M in cash against an annual operating cash burn of $88.2M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Oruka Therapeutics Inc's Piotroski F-Score?
Oruka Therapeutics Inc (ORKA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Oruka Therapeutics Inc's earnings high quality?
Oruka Therapeutics Inc (ORKA) has an earnings quality ratio of 0.84x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.